Pharmacokinetic Assessment of Tacrolimus Exposure Before and After a Switch From Twice Daily Immediate-release (Prograf) to Once-daily Prolonged Release Tacrolimus (Envarsus)

At a glance
Trial Overview
Trial Details
Interventions
Trial Centres
- Investigators
- Centres
Trial History
References

X

Trial Profile

Pharmacokinetic Assessment of Tacrolimus Exposure Before and After a Switch From Twice Daily Immediate-release (Prograf) to Once-daily Prolonged Release Tacrolimus (Envarsus)

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 02 Mar 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tacrolimus (Primary)
Indications Allotransplant rejection
Focus Pharmacokinetics
Acronyms ENVARSWITCH

Most Recent Events

22 May 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2020.
22 May 2019 Planned primary completion date changed from 1 May 2018 to 1 May 2020.
15 Jun 2017 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com